Definitive Contract 75N93020C00047
Award Date
8/21/20
Potential Completion Date
8/20/22
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This SBIR Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, valued at $299,868, was awarded to Hbvtech of Germantown, Maryland. The contract supports research outlined in Topic 084 of the solicitation, which sought proposals for antiviral drugs to cure chronic hepatitis B virus infection. The firm-fixed price contract is a total small business set-aside running from August 2020 through October 2021. The award advances the NIH/NIAID's...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000.00 firm-fixed-price definitive contract to Zymeron Corporation, a minority-owned small business, to provide rapid point-of-care tests to quantify hepatitis C virus. The contract has an estimated completion date of August 30, 2022 and was awarded on August 31, 2021. Zymeron is a research-based biotechnology company that develops innovative technologies...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
Zymeron Corporation has been awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Zymeron will develop a novel nanoparticle delivery system to elicit a potent and long-lasting antibody response and broad neutralizing activity against HIV, as requested under the Centers for Disease Control and Prevention and NIH solicitation seeking...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.55 million definitive cost plus fixed fee contract to Hbvtech of Germantown, Maryland to perform work under Small Business Innovation Research Phase II Topic 84, entitled "Antiviral Drugs to Cure Chronic Hepatitis B Virus Infection." The contract period of performance spans from September 1, 2022 through August 25, 2025. Under this award,...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Zymeron Corporation, a minority-owned small business, to complete Phase II tasks for a Small Business Innovation Research (SBIR) program topic. The contract supports Zymeron's research and development of technologies focused on areas like protein degradation, antibacterials, antivirals, and drug delivery...
This SBIR Phase I contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases aims to develop a novel HIV vaccine co-delivery system. Zymeron Corporation will receive $300,000 to create an injectable thermosensitive hydrogel encapsulating polyroxatane-based self-amplifying RNA nanoparticles and GM-CSF cytokine adjuvant for targeted delivery. The research will take place in Research Triangle Park, North Carolina over approximately 22 months. This...